Comparative Pharmacology
Head-to-head clinical analysis: ALCAINE versus NESACAINE MPF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALCAINE versus NESACAINE MPF.
ALCAINE vs NESACAINE-MPF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.
Nesacaine-MPF (chloroprocaine) is an ester-type local anesthetic that stabilizes neuronal membranes by inhibiting sodium ion influx, thereby blocking impulse conduction in nerve fibers.
1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.
1% solution: 2.5-30 mL (25-300 mg) subcutaneously or locally; maximum 30 mL per dose. 2% solution: 1.25-15 mL (25-300 mg) subcutaneously or locally; maximum 15 mL per dose.
None Documented
None Documented
Terminal elimination half-life: 0.4–1.2 minutes (rapid enzymatic hydrolysis by plasma esterases); clinical significance: ultra-short duration limits systemic toxicity.
Terminal half-life: 3-4 hours (adults); prolonged in hepatic or renal impairment.
Renal excretion of parent drug and metabolites: <5% unchanged.
Renal excretion of metabolites; <10% unchanged drug. Biliary/fecal elimination minor.
Category C
Category C
Local Anesthetic
Local Anesthetic